Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Address: Av. Doutor Cardoso de Melo, 1.184, 17º andar Vila Olimpia São Paulo – SP – Brasil Cep: 04548-004,Brazil
Tel: +55 11 3568-3400
Web: http://www.biogenidec.com.br/
Biogen Idec Inc. (NASDAQ: BIIB) is a global biotechnology leader with products in oncology, neurology and immunology. Biogen Idec is committed to transforming scientific discoveries into advances and health care. The company’s include the discovery, research, development and biomanufacturing of medicine and a global commercial infrastructure.
Biogen Idec pursues the creativity of science with passion and discipline. For over 25 years, the company has grown through the discovery, development and commercialization of innovative products themselves and through strategic alliances.
Scientific excellence that achieves new standards of care drives the company’s work. Currently, more than twenty products are in clinical development to meet a number of important medical needs.
Biogen Idec has affiliates in Brazil, Canada, Australia, Japan and throughout Europe, including the international headquarters in Zug, Switzerland. The company currently employs approximately 3,600 people worldwide.
In Brazil, Biogen Idec is focused on the Multiple Sclerosis market, as an expert company in the disease, and is responsible for organizing World MS Day activities in the country.
Avonex, Tysabri
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there…
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
See our Cookie Privacy Policy Here
